İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
FMC Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $880.4M | |
|---|---|---|
| Revenue (ttm) | 3.3B | |
| Net income (ttm) | -2.8B | |
| EPS (ttm) | -$22.0 | |
| Shares out | 155.5M | |
| P/E (forward) | 5.7x | |
| Dividend | $0.32 (7.20%) | |
| Volume | 6,421,718 | |
| Beta | 0.46 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $5.05B | $5.80B | $4.49B | $4.25B | $3.47B | -8.9% |
| Gross profit | $2.16B | $2.33B | $1.83B | $1.65B | $1.28B | -12.2% |
| Operating income | $1.03B | $1.14B | $555.6M | $506.5M | $-1.63B | — |
| Net income | $739.6M | $736.5M | $1.32B | $341.1M | $-2.24B | — |
| EPS (diluted) | $5.73 | $5.81 | $10.53 | $2.72 | $-17.88 | — |
| EBITDA | $1.20B | $1.30B | $786.2M | $827.9M | $-84.7M | — |
| R&D | $304.7M | $314.2M | $328.8M | $278.0M | $266.1M | -3.3% |
| SG&A | $714.1M | $775.2M | $734.3M | $644.6M | $684.9M | -1.0% |
Recent company headlines from major financial publishers.
The Base scenario envisions our primary valuation target of $23.78, assigned a 55.0% probability weighting and offering an implied return of 320.1% from the analysis price of $5.66 (as of 2026-10-16). In this pathway, distributor inventory destocking in Latin America and North America concludes through FY2027, restoring wholesale procurement toward equilibrium with grower field applications. Operating margins normalize toward historical mid-cycle levels as operating leverage returns across manufacturing assets, while proprietary formulations defend diamide insecticide market share.
The Bull scenario models an upside valuation target of $32.51, assigned a 20.0% probability weighting and delivering an implied return of 474.4% from $5.66 (as of 2026-10-16). Under this trajectory, channel inventory depletion triggers an aggressive restocking cycle across South America, supported by robust pest pressure and expanding planted acreage. High-margin specialty formulations accelerate operating margin expansion beyond mid-cycle targets, while substantial free cash flow generation enables accelerated debt paydown.
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 6.4% | $26.1 | $27.0 | $27.9 | $28.9 | $30.1 |
| 6.9% | $24.2 | $24.9 | $25.6 | $26.5 | $27.4 |
| 7.4% | $22.6 | $23.2 | $23.8 | $24.4 | $25.2 |
| 7.9% | $21.3 | $21.7 | $22.2 | $22.8 | $23.3 |
| 8.4% | $20.1 | $20.5 | $20.9 | $21.3 | $21.8 |
Upcoming earnings date and setup when available.
Her ay yayımlanan araştırma sürümünün taşıdığı derecelendirme. Bir derecelendirme, analiz tarihindeki fiyatı gerçeğe uygun değerle karşılaştırır; tahminin doğru çıkıp çıkmadığının kaydı değildir.
| Yıl | Oca | Şub | Mar | Nis | May | Haz | Tem | Ağu | Eyl | Eki | Kas | Ara |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |